Retrospective Study
Copyright ©The Author(s) 2021.
World J Gastroenterol. Sep 7, 2021; 27(33): 5610-5621
Published online Sep 7, 2021. doi: 10.3748/wjg.v27.i33.5610
Table 1 Baseline characteristics of the study population
Characteristics
PNI+ (n = 144)
PNI- (n = 159)
P value
The training set(n = 242)
The validation set(n = 61)
P value
Age (mean ± SD, yr)58.9 ± 11.858.9 ± 11.70.95258.4 ± 11.960.8 ± 10.20.162
Sex (male/female)77/6793/660.379140/10230/310.223
Volume (cm3) 19.720.80.13220.120.80.847
Location10.0750.045
Middle-low1019616433
High43637828
cT stage (T1-2/T3/T4)25/98/2157/90/12< 0.00161/156/2521/32/80.222
cN stage (N0/N1/N2)31/52/6175/59/25< 0.00189/84/6917/27/170.313
Neoadjuvant therapy (+/-)25/11937/1220.20351/19111/500.599
CEA (+/-) (positive ≥ 5 ng/mL)77/6756/1030.001107/13526/350.823
CA19-9 (+/-) (positive ≥ 30 U/mL)43/10135/1240.11964/17814/470.577
CA125 (+/-) (positive ≥ 24 U/mL)20/12415/1440.22620/2223/580.378
pT stage (T1/T2/T3/T4)0/15/117/128/44/95/12< 0.0016/48/171/172/11/41/70.584
pN stage (0/N1/N2)29/74/4181/56/22< 0.00188/101/5322/29/100.579
Stage (Ⅰ/Ⅱ/Ⅲ)10/28/11538/43/78< 0.00140/48/1548/14/390.731
Histologic grade (G1/G2/G3)1/105/382/133/240.0142/189/511/49/110.523
Rad-score0.60 ± 0.190.40 ± 0.20< 0.0010.50±0.210.49 ± 0.230.805